It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX) . Shares have added about 5.7% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Recursion Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimat ...

Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) are pioneering the use of artificial intelligence (AI) in drug discovery for various indications across different disease areas. They leverage machine learning and computational platforms to accelerate the development of novel therapeutics, positioning themselves at the forefront of the AI-driven biotech sector.Both RXRX and SDGR have the potential to shift the paradigm of drug discovery and development, which has historically been complex, costly, and ...

Recursion Pharmaceuticals (RXRX) shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, as both earnings and revenues missed estimates, last week. In the absence of an approved product, RXRX only recognizes collaboration and grant revenues from its partners.The decline was further aggravated after Recursion Pharmaceuticals discontinued the development of its lead candidate, REC-994, for treating ...

Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline. Recursion was also hit by a survey revealing that the biotech industry expects President Donald Trump's federal research cuts will make raising capital more challenging.By the numbersRecursion report ...

Shares of Recursion Pharmaceuticals (RXRX -11.57%) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P 500 and Nasdaq Composite both slipped by 0.6%.The data from an April survey revealed Tuesday showed that the biotech industry is fearful that President Donald Trump's federal research cuts will make raising capital more challenging. This comes just a day after Recursion revealed its disappointing first-quarter earni ...

Recursion Pharmaceuticals (RXRX) reported a loss of 50 cents per share in the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 39 cents per share in the year-ago quarter.In the absence of an approved product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. Total revenues in the reported quarter amounted to $14.7 million, up 7% year over year, primarily driven by the timing of projects from R ...

股价表现 - Recursion Pharmaceuticals周一开盘表现不佳 股价在盘中交易中下跌15% 同期标普500指数仅下跌0.3% [1] 财务数据 - 第一季度收入1470万美元 高于2024年同期的1380万美元 [3] - 营业成本几乎翻倍 净亏损扩大至2.02亿美元(每股0.50美元) 去年同期为9100万美元 [4] - 两项关键数据均略低于分析师预期 分析师平均预测收入略低于1500万美元 每股净亏损0.49美元 [4] 业务发展 - 公司积极利用人工智能技术进行新药研发 主要开发癌症治疗药物 同时有两项罕见病项目 [5] - 目前所有研发项目均未进入后期阶段 投资者可能期待更多进展 [5] - 人工智能在医药领域应用仍属新兴因素 如有效利用可显著加速药物发现和开发进程 [6]

Recursion Pharmaceuticals (RXRX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Company Participants Chris Gibson - Co-Founder & CEONajat Khan - Chief R&D Officer, Chief Commercial Officer and DirectorBen Taylor - CFO & President Recursion UK Chris Gibson Hi, everybody. My name is Chris Gibson, cofounder and CEO of Recursion, and I'm delighted to welcome you to our learnings call this morning. We're gonna go ahead and get started. Perfect. So, of course, important to note that we're gonna be providing forwa ...

Recursion Pharmaceuticals (RXRX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Company Participants Chris Gibson - Co-Founder & CEONajat Khan - Chief R&D Officer, Chief Commercial Officer and DirectorBen Taylor - CFO & President Recursion UK Chris Gibson Hi, everybody. My name is Chris Gibson, cofounder and CEO of Recursion, and I'm delighted to welcome you to our learnings call this morning. We're gonna go ahead and get started. Perfect. So, of course, important to note that we're gonna be providing forwa ...

财务表现 - 公司季度每股亏损0 50美元 超出市场预期的0 44美元亏损 去年同期每股亏损0 39美元 [1] - 季度营收1475万美元 低于市场预期26 82% 去年同期营收1379万美元 [2] - 过去四个季度均未达到每股收益预期 仅有一次超过营收预期 [2] 市场表现 - 年初至今股价下跌15 7% 同期标普500指数下跌3 3% [3] - 当前Zacks评级为3级(持有) 预计近期表现与市场持平 [6] 未来展望 - 下季度共识预期每股亏损0 40美元 营收1995万美元 本财年预期每股亏损1 34美元 营收7646万美元 [7] - 盈利预测修订趋势呈现混合状态 未来可能随财报发布调整 [6] 行业比较 - 所属医疗-制药行业在Zacks行业排名中位列前25% [8] - 同业公司Ironwood Pharmaceuticals预计季度每股亏损0 05美元(同比恶化150%) 营收5945万美元(同比下降20 6%) [9]